Last reviewed · How we verify
Antiretroviral/Anti HIV
Antiretroviral drugs inhibit HIV replication by targeting viral enzymes or blocking viral entry into CD4+ T cells.
Antiretroviral drugs inhibit HIV replication by targeting viral enzymes or blocking viral entry into CD4+ T cells. Used for HIV-1 infection (treatment and prevention).
At a glance
| Generic name | Antiretroviral/Anti HIV |
|---|---|
| Also known as | Antiretroviral Combinations |
| Sponsor | MSD Pharmaceuticals LLC |
| Drug class | Antiretroviral agent (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitor) |
| Target | HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, or CXCR4 (depending on specific agent) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Antiretroviral therapy (ART) encompasses multiple drug classes that work at different stages of the HIV lifecycle. Common mechanisms include reverse transcriptase inhibitors (blocking viral RNA conversion to DNA), protease inhibitors (preventing viral protein maturation), integrase inhibitors (blocking viral DNA integration into the host genome), and entry inhibitors (preventing viral attachment or fusion with CD4+ cells). Combination therapy is standard to suppress viral replication and prevent resistance.
Approved indications
- HIV-1 infection (treatment and prevention)
Common side effects
- Nausea and gastrointestinal disturbance
- Headache
- Diarrhea
- Rash
- Lipodystrophy and metabolic changes
- Hepatotoxicity
- Peripheral neuropathy
Key clinical trials
- The T Cell Activator of Cell Killing ("TACK") IT ON" STUDY (NA)
- Teamwork Makes the Dream Work (NA)
- Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women (PHASE2)
- Bone Mineral Density (BMD) in HIV Infection (NA)
- Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment (PHASE2)
- Project neuroARTEMIS (NA)
- Contributing Factors for Poor HIV Treatment Response in Children With TB/HIV Coinfection
- A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antiretroviral/Anti HIV CI brief — competitive landscape report
- Antiretroviral/Anti HIV updates RSS · CI watch RSS
- MSD Pharmaceuticals LLC portfolio CI